Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.

The journal of prevention of Alzheimer's disease·2026
Same author

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.

medRxiv : the preprint server for health sciences·2026
Same author

Interchangeability of CSF and PET to identify Alzheimer's disease pathology.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Neuropathological correlates of age and sex differences in 18F-flortaucipir PET.

Brain : a journal of neurology·2026
Same author

Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults.

The journal of prevention of Alzheimer's disease·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Vikas Kotari1, Karen Chilcott Holdridge2, Roy Yaari2

  • 1Eli Lilly and Company, Indianapolis, IN, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

这项研究分析了前临床阿尔茨海默病 (AD) 参与者的定子发射断层扫描 (PET) 扫描. 结果显示tau沉积模式与其他临床前AD队列相似,即使在那些轻度认知障碍的人中也是如此.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 放射学 放射学是一门学科.
  • 老年学是一门学科.

背景情况:

  • 临床前阿尔茨海默氏症 (AD) 的特点是粉样蛋白积累,但保持认知能力.
  • 在无症状阿尔茨海默病 (A4) 试验中,大多数参与者缺乏显著的积.
  • 在TRAILBLAZER-ALZ 3试验中,研究了donanemab在临床前AD的疗效.

研究的目的:

  • 描述和比较TRAILBLAZER-ALZ 3,A4和TRAILBLAZER-ALZ 2研究中的基线定子发射断层扫描 (PET) 扫描.
  • 在临床前阿尔茨海默病患者群体中分析tau分布,使用flortaucipir F 18 (FTP) PET扫描.

主要方法:

  • 利用了来自TRAILBLAZER-ALZ 3试验的310名参与者的数据,根据临床痴呆症评分-全球分数 (CDR-GS 0和CDR-GS 0.5) 分类.
  • 雇佣了flortaucipir F 18 (FTP) tau PET成像和分析全球tau负担和区域模式的建立管道.
  • 使用标准化吸收值比率 (SUVR) 切割点定义的tau阳性 (>1.11对于阳性扫描,>1.46对于高tau水平).

主要成果:

  • 13.3%的CDR0和25.5%的CDR0.5参与者显示出阳性PET扫描 (SUVR>1.11).
  • 在两个小组中,中侧叶表现出最高的区域基线SUVRs.
  • 平均SUVRs表明了一种连续的沉积模式:中部 > 侧面 > 顶部 > 前叶.

结论:

  • 在TRAILBLAZER-ALZ 3中基线tau PET模式与其他临床前AD种群一致,包括CDR0.5亚组.
  • 观察到的沉积模式支持从中间叶到额叶的连续进展.
  • 计划进行进一步的区域分析,以更深入地了解分布.